We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Paclitaxel Injection, USP 300mg/50mL vial (Sagent, USA)
Section 19A approved medicine
Paclitaxel Injection, USP 300mg/50mL vial (Sagent, USA)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 517
Phone
1800 181 060
Approved until
Status
Current
Medicines in short supply/unavailable
PACLITAXEL ACCORD paclitaxel 300 mg/50 mL concentrated injection vial ARTG - 219556
Indication(s)
Paclitaxel is indicated for:
- the primary treatment of ovarian cancer in combination with a platinum agent.
- the treatment of metastatic carcinoma of the ovary after failure of standard therapy.
- the treatment of metastatic carcinoma of the breast after failure of standard therapy.
- adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide.
Images
